Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease

[1]  J. Rose,et al.  Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. , 2014, Antiviral research.

[2]  M. Whitt,et al.  Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease , 2013, Virology Journal.

[3]  R. Speare,et al.  Response of Australian veterinarians to the announcement of a Hendra virus vaccine becoming available. , 2013, Australian Veterinary Journal.

[4]  C. Broder,et al.  Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months , 2013, Virology Journal.

[5]  K. Jansen,et al.  Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice. , 2013, Immunology letters.

[6]  F. Cosset,et al.  Protection Against Henipavirus Infection by Use of Recombinant Adeno-Associated Virus–Vector Vaccines , 2012, The Journal of infectious diseases.

[7]  H. Raoul,et al.  Type I Interferon Signaling Protects Mice From Lethal Henipavirus Infection , 2012, The Journal of infectious diseases.

[8]  J. Bergfeld,et al.  Transmission Routes for Nipah Virus from Malaysia and Bangladesh , 2012, Emerging infectious diseases.

[9]  E. Wang,et al.  A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine , 2012, Journal of Virology.

[10]  Heinz Feldmann,et al.  A Hendra Virus G Glycoprotein Subunit Vaccine Protects African Green Monkeys from Nipah Virus Challenge , 2012, Science Translational Medicine.

[11]  E. Gurley,et al.  Epidemiology of henipavirus disease in humans. , 2012, Current topics in microbiology and immunology.

[12]  J. Epstein,et al.  Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. , 2011, The American journal of tropical medicine and hygiene.

[13]  C. Broder,et al.  A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. , 2011, Vaccine.

[14]  K. Mansfield,et al.  Clinical Outcome of Henipavirus Infection in Hamsters Is Determined by the Route and Dose of Infection , 2011, Journal of Virology.

[15]  J. Rose,et al.  Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach , 2010, Journal of Virology.

[16]  M. Whitt.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. , 2010, Journal of Virological Methods.

[17]  C. Broder,et al.  Development of an Acute and Highly Pathogenic Nonhuman Primate Model of Nipah Virus Infection , 2010, PloS one.

[18]  N. Tordo,et al.  Experimental Infection of Squirrel Monkeys with Nipah Virus , 2010, Emerging infectious diseases.

[19]  C. Broder,et al.  A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection , 2009, PLoS pathogens.

[20]  C. Broder,et al.  Chloroquine Administration Does Not Prevent Nipah Virus Infection and Disease in Ferrets , 2009, Journal of Virology.

[21]  C. Broder,et al.  A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats , 2008, Vaccine.

[22]  Y. Berhane,et al.  Bacterial infections in pigs experimentally infected with Nipah virus. , 2008, Transboundary and emerging diseases.

[23]  Stephen P. Luby,et al.  Person-to-Person Transmission of Nipah Virus in a Bangladeshi Community , 2007, Emerging infectious diseases.

[24]  P. Daniels,et al.  Experimental Nipah virus infection in pteropid bats (Pteropus poliocephalus). , 2007, Journal of comparative pathology.

[25]  C. Broder,et al.  Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine , 2006, Journal of Virology.

[26]  Yohannes Berhane,et al.  Recombinant Nipah Virus Vaccines Protect Pigs against Challenge , 2006, Journal of Virology.

[27]  H. Contamin,et al.  Poly(I)-Poly(C12U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[28]  V. Guillaume,et al.  Antibody Prophylaxis and Therapy against Nipah Virus Infection in Hamsters , 2006, Journal of Virology.

[29]  J. A. Comer,et al.  Nipah Virus-associated Encephalitis Outbreak, Siliguri, India , 2006, Emerging infectious diseases.

[30]  K. Subbarao,et al.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.

[31]  Y. Berhane,et al.  Invasion of the Central Nervous System in a Porcine Host by Nipah Virus , 2005, Journal of Virology.

[32]  R. M. Hendry,et al.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. , 2004, AIDS research and human retroviruses.

[33]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[34]  A. Roberts,et al.  Complete Protection from Papillomavirus Challenge after a Single Vaccination with a Vesicular Stomatitis Virus Vector Expressing High Levels of L1 Protein , 2004, Journal of Virology.

[35]  V. Guillaume,et al.  Nipah Virus: Vaccination and Passive Protection Studies in a Hamster Model , 2004, Journal of Virology.

[36]  J. Rose,et al.  Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. , 2003, The Journal of general virology.

[37]  A. Roberts,et al.  Intranasal Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing Cottontail Rabbit Papillomavirus L1 Protein Provides Complete Protection against Papillomavirus-Induced Disease , 2002, Journal of Virology.

[38]  A. Hyatt,et al.  Experimental Nipah virus infection in pigs and cats. , 2002, Journal of comparative pathology.

[39]  A. Roberts,et al.  Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge , 2001, Journal of Virology.

[40]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[41]  W. Bellini,et al.  Molecular biology of Hendra and Nipah viruses. , 2001, Microbes and infection.

[42]  A. Roberts,et al.  Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[43]  V. ter meulen,et al.  Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies , 2000, Journal of Virology.

[44]  Adeeba Kamarulzaman,et al.  Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia , 1999, The Lancet.

[45]  A. Roberts,et al.  Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors , 1999, Journal of Virology.

[46]  L. Wang,et al.  Virology Journal , 1966, Nature.